Publications

363 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:
  1. Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

    The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

    Report | 17-01-2022

  2. GVS advice on volanesorsen (Waylivra)

    The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

    Report | 10-01-2022

  3. GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

    The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...

    Report | 21-12-2021

  4. Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

    The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

    Report | 15-12-2021

  5. GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

    The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...

    Report | 01-12-2021

  6. GVS advice fostemsavir (Rukobia®) for the treatment of adults with multidrug resistant HIV-1 infection

    The National Health Care Institute recommends the Minister to include fostemsavir (Rukobia®) in the GVS on List 1B and List 2 of ...

    Report | 01-12-2021

  7. Package advice for the lock procedure drug osimertinib (Tagrisso®)

    The National Health Care Institute has completed its assessment whether osimertinib (Tagrisso®) can be included in the insured ...

    Report | 15-11-2021

  8. Package advice venetoclax (Venclyxto®)

    The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) can be included in the insured ...

    Report | 10-11-2021

  9. GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease

    The National Health Care Institute advises the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment ...

    Report | 02-11-2021

  10. GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

    National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the ...

    Report | 26-10-2021